新冠肺炎出院患者康复评估与治疗

注册号:

Registration number:

ChiCTR2100051530 

最近更新日期:

Date of Last Refreshed on:

2022-04-12 15:46:26 

注册时间:

Date of Registration:

2021-09-26 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

新冠肺炎出院患者康复评估与治疗

Public title:

Rehabilitation assessment and treatment for Discharged COVID-19 patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

新冠肺炎出院患者康复评估与治疗

Scientific title:

Rehabilitation assessment and treatment for Discharged COVID-19 patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李正良 

研究负责人:

夏文广 

Applicant:

Li Zhengliang 

Study leader:

Xia Wenguang 

申请注册联系人电话:

Applicant telephone:

+86 17771435723

研究负责人电话:

Study leader's
telephone:

+86 1377897279

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lizhengliang23@163.com

研究负责人电子邮件:

Study leader's E-mail:

docxwg@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖北省武汉市江汉区菱角湖路11号

研究负责人通讯地址:

湖北省武汉市江汉区菱角湖路11号

Applicant address:

11 Lingjiaohu Road, Jianghan District, Wuhan, Hubei

Study leader's address:

11 Lingjiaohu Road, Jianghan District, Wuhan, Hubei

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

湖北省中西医结合医院

Applicant's institution:

Hubei Provincial Hospital of Integrated Chinese and Western Medicine

研究负责人所在单位:

湖北省中西医结合医院

Affiliation of the Leader:

Hubei Provincial Hospital of Integrated Chinese and Western Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020伦审第(研020)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

湖北省中西医结合医院伦理委员会

Name of the ethic committee:

Ethics Committee of Hubei Provincial Hospital of Integrated Chinese and Western Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020-12-15 00:00:00

伦理委员会联系人:

张拯

Contact Name of the ethic committee:

Zhang Zheng

伦理委员会联系地址:

湖北省武汉市江汉区菱角湖路11号

Contact Address of the ethic committee:

11 Lingjiaohu Road, Jianghan District, Wuhan, Hubei

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

湖北省中西医结合医院

Primary sponsor:

Hubei Provincial Hospital of Integrated Chinese and Western Medicine

研究实施负责(组长)单位地址:

湖北省武汉市江汉区菱角湖路11号

Primary sponsor's address:

11 Lingjiaohu Road, Jianghan District, Wuhan, Hubei

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖北

市(区县):

武汉

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

湖北省中西医结合医院

具体地址:

江汉区菱角湖路11号

Institution
hospital:

Hubei Provincial Hospital of Integrated Chinese and Western Medicine

Address:

11 Lingjiaohu Road, Jianghan District

经费或物资来源:

湖北省卫生健康委

Source(s) of funding:

Health Commission of Hubei Province

研究疾病:

新冠肺炎  

Target disease:

Novel Coronavirus Pneumonia (COVID-19)

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

对新冠肺炎出院患者进行康复评估与治疗,并随访疗效。  

Objectives of Study:

To estimate and provide rehabilitation intervention to COVID-19 survivors.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.合并患有严重心脑血管、肝、肾、恶性肿瘤、血液系统疾病者、精神类疾病患者;
2.严重意识障碍、痴呆或患有某些疾病影响疗效评价,如失语、视听障碍;
3.无法或不愿意配合康复评估者;
4.认知障碍,精神障碍,长期酗酒或有违禁药物服用史;
5.处于妊娠期、哺乳期的女性,或近6个月内有妊娠计划者;
6.正在参与或近3个月参与其他临床试验者;
7.研究者判断不适宜参加本试验的患者。

Exclusion criteria:

1. Patients with severe cardiovascular, cerebrovascular, liver, kidney, malignant tumors, hematological diseases, and mental diseases;
2. Severe disturbance of consciousness, dementia or suffering from certain diseases affect the evaluation of curative effect, such as aphasia, visual and hearing impairment;
3. Those who are unable or unwilling to cooperate with rehabilitation assessment;
4. Cognitive disorders, mental disorders, long-term alcohol abuse or a history of illegal drug use;
5. Women who are pregnant or breastfeeding, or have pregnancy plans in next six months;
6. Those who are participating in other clinical trials or have participated in other clinical trials in the past 3 months; 7. Patients judged by the investigator to be unsuitable to participate in this trial.

研究实施时间:

Study execute time:

From 2021-09-28 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-09-30 00:00:00 To 2022-01-30 00:00:00

干预措施:

Interventions:

组别:

运动训练组

样本量:

40

Group:

exercise training group

Sample size:

干预措施:

运动训练+健康教育

干预措施代码:

Intervention:

exercise training plus educational instructions

Intervention code:

组别:

中药组

样本量:

40

Group:

traditional Chinese medicine group

Sample size:

干预措施:

中药+健康教育

干预措施代码:

Intervention:

traditional Chinese medicine plus educational instructions

Intervention code:

组别:

对照组

样本量:

40

Group:

control group

Sample size:

干预措施:

健康教育

干预措施代码:

Intervention:

educational instructions

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖北 

市(区县):

武汉 

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

湖北省中西医结合医院 

单位级别:

三级甲等 

Institution
hospital:

Hubei Provincial Hospital of Integrated Chinese and Western Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

疲劳量表

指标类型:

主要指标

Outcome:

fatigue scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

六分钟步行距离

指标类型:

次要指标

Outcome:

6 minute walk distance

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

下肢肌力

指标类型:

次要指标

Outcome:

strength of lower limber muscles

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量

指标类型:

次要指标

Outcome:

Quality of life

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

呼吸困难程度评分mMRC

指标类型:

次要指标

Outcome:

mMRC dyspnea scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

负责随机的研究人员采用SAS产生随机序列

Randomization Procedure (please state who generates the random number sequence and by what method):

SAS was used to generate random sequences

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

未说明 请阅读网页注册指南中关于“原始数据共享”的内容。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not stated

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

通过病例记录表采集记录数据,建立电子数据库管理数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Collect record data through case record table and establish electronic database management data

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-09-26 22:49:38